We’re excited to share a major milestone in the field of electrophysiology — the First-in-Human use of the ViewFlex™ SE ICE catheter in combination with EnSite™ X v5 is officially underway at Arrhythmia Research Group and St. Bernards Healthcare as part of the ViewFlex SE Trial.

This launch represents more than a new catheter. It marks a leap forward in integrating AI-assisted mapping, real-time contact assessment, and streamlined ICE navigation into the EP workflow.

At CardioServ, we are proud to have played a key role in this advancement — leading the testing and validation of the AI technology that supports this system.

AI in ICE: The Role of CardioServ

Artificial intelligence is only as powerful as it is accurate, reliable, and clinically validated. That’s exactly where our team stepped in.

CardioServ served as the AI testing and validation partner on this project — specifically focused on the intracardiac echocardiography (ICE) component. Our goal was to ensure that the machine learning models powering the catheter’s imaging and mapping functionality were not just intelligent, but also clinically trustworthy.

To achieve this, our responsibilities included:

• Manually measuring thousands of ICE images across a range of views and anatomical variations
• Reviewing AI-generated measurements against expert-established benchmarks
• Identifying edge cases and anomalies to improve model performance
• Providing clinical insight and feedback to guide ongoing refinements

In doing so, we helped bridge the gap between data science and real-world clinical readiness. As a result, the AI-assisted features now empower electrophysiologists with greater confidence at the bedside.

Behind the Breakthrough: Celebrating the AI Validation Teams

A milestone like this doesn’t happen without people. We’re proud to recognize the talented individuals who made this possible — especially our dedicated ICE AI validation team, whose work was essential in bringing this technology to life.

AI Intracardiac Echocardiography (ICE) Validation Team

Led by Fabienne Innocent, a founding Echo team member, this group played a critical role in validating the AI models used in the ViewFlex™ SE + EnSite™ X v5 system.

Team Members:

• Fabienne Innocent – Team Lead & pioneer team member
• Mickel Campbell
• Saidah Morisseau

Throughout development, they meticulously measured and reviewed thousands of ICE images. Their attention to detail ensured that AI outputs were accurate, consistent, and clinically reliable for First-in-Human use.

This team worked across disciplines, solved complex cases, and stayed focused on accuracy, even during late nights and tight timelines. Without their efforts, this milestone wouldn’t have been possible.

AI Echocardiography Data Analyst Team

In parallel, our AI Echocardiography Data Analyst Team, led by Melissa Dearman, a pioneer team member, has been instrumental in setting the foundation for AI validation across echocardiography.

Team Members:

• Rachel Miller – Pioneer team member
• Liane Slicker
• Sydney Hinderer
• Tamara Hubbard

Additionally, we extend our thanks to Jackie Aslan, whose early contributions as part of the original pioneer team helped launch CardioServ’s AI program.

What Makes This Technology Special?

Developed through a collaboration between Abbott and iCardio.ai, the new ViewFlex™ SE catheter and EnSite™ X v5 software introduce a smDeveloped through a collaboration between Abbott and iCardio.ai, the new ViewFlex™ SE catheter and EnSite™ X v5 software introduce a smarter, more streamlined EP workflow.

Watch video here

Here’s what stands out:

• AI-assisted map creation with physician-ready geometry
• Real-time contact assessment via the new Contact Index
• Simplified ICE navigation using single-handed deflection with auto-lock
• Color-coded deflection indicators for intuitive in-procedure control
• Cleaner workflows enabled by a single catheter cable and sterile tip-to-connector design

Together, these features support faster procedures, improved lesion validation, and safer outcomes — especially in Pulsed Field Ablation (PFA), where precise catheter contact is essential.

Why It Matters

Technology in healthcare only matters if it improves outcomes and enhances workflows. This innovation does both — and AI plays a central role.

CardioServ’s contribution to this project reinforces our mission: to advance cardiovascular care through data-driven innovation, rigorous validation, and a relentless focus on quality. We’re proud to have helped validate a technology that’s already impacting lives in real-world procedures — and we’re excited for what comes next.

Better imaging. Better data. Better outcomes.

Want to learn more about how CardioServ supports AI development through clinical testing and validation? Contact us and let’s talk!